Effect of interaction is not clear, use caution. Use Caution/Monitor.cyclosporinecyclosporine will increase the level or effect of sulfasalazine by Other (see comment). Use Caution/Monitor. Cyclosporine, a BCRP inhibitor, may increase levels of sulfasalazine (a BCRP substrate) when combined.dalteparindalteparin and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.darolutamidedarolutamide will increase the level or effect of sulfasalazine by Other (see comment). Modify Therapy/Monitor Closely. Darolutamide is a BCRP inhibitor. Avoid coadministration with BCRP inhibitors. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information).deflazacortsulfasalazine, deflazacort. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.dexamethasonesulfasalazine, dexamethasone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.diclofenacdiclofenac and sulfasalazine both increase anticoagulation. Use Caution/Monitor.diclofenac and sulfasalazine both increase serum potassium. Use Caution/Monitor.dicloxacillindicloxacillin, sulfasalazine. Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.dicloxacillin, sulfasalazine. Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.diflunisaldiflunisal and sulfasalazine both increase anticoagulation. Use Caution/Monitor.diflunisal and sulfasalazine both increase serum potassium. Use Caution/Monitor.digoxinsulfasalazine and digoxin both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Sulfasalazine >2 g/day.dobutaminesulfasalazine increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.dong quaisulfasalazine and dong quai both increase anticoagulation. Use Caution/Monitor.dopexaminesulfasalazine increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.doxazosinsulfasalazine decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.drospirenonedrospirenone and sulfasalazine both increase serum potassium. Modify Therapy/Monitor Closely.duloxetineduloxetine, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.eltrombopageltrombopag increases levels of sulfasalazine by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear.eluxadolineeluxadoline increases levels of sulfasalazine by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered BCRP substrates. .enalaprilsulfasalazine decreases effects of enalapril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.enalapril, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.encorafenibencorafenib will increase the level or effect of sulfasalazine by Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a BCRP inhibitor) may increase the concentration and toxicities of BCRP substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates.enoxaparinenoxaparin and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.ephedrinesulfasalazine increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrinesulfasalazine increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrine racemicsulfasalazine increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.epoprostenolsulfasalazine and epoprostenol both increase anticoagulation. Use Caution/Monitor.eprosartaneprosartan and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of eprosartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.eprosartan, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.escitalopramescitalopram, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.esmololesmolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of esmolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.ethacrynic acidsulfasalazine increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.etodolacetodolac and sulfasalazine both increase anticoagulation. Use Caution/Monitor.etodolac and sulfasalazine both increase serum potassium. Use Caution/Monitor.fennelsulfasalazine and fennel both increase anticoagulation. Use Caution/Monitor.fenoprofenfenoprofen and sulfasalazine both increase anticoagulation. Use Caution/Monitor.fenoprofen and sulfasalazine both increase serum potassium. Use Caution/Monitor.feverfewsulfasalazine and feverfew both increase anticoagulation. Use Caution/Monitor.fludrocortisonesulfasalazine, fludrocortisone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.fluoxetinefluoxetine, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.flurbiprofenflurbiprofen and sulfasalazine both increase anticoagulation. Use Caution/Monitor.flurbiprofen and sulfasalazine both increase serum potassium. Use Caution/Monitor.fluvoxaminefluvoxamine will increase the level or effect of sulfasalazine by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by plateletsfondaparinuxfondaparinux and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.formoterolsulfasalazine increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.forskolinsulfasalazine and forskolin both increase anticoagulation. Use Caution/Monitor.fosinoprilsulfasalazine decreases effects of fosinopril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.fosinopril, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.fostamatinibfostamatinib will increase the level or effect of sulfasalazine by decreasing metabolism. Use Caution/Monitor. Concomitant use of fostamatinib may increase concentrations of BCRP substrate drugs. Monitor for toxicities of BCRP substrate drug that may require dosage reduction when given concurrently with fostamatinib.fostemsavirfostemsavir will increase the level or effect of sulfasalazine by Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits BCRP transporters. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir. furosemidesulfasalazine increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.garlicsulfasalazine and garlic both increase anticoagulation. Use Caution/Monitor.gentamicinsulfasalazine increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.gingersulfasalazine and ginger both increase anticoagulation. Use Caution/Monitor.ginkgo bilobasulfasalazine and ginkgo biloba both increase anticoagulation. Use Caution/Monitor.glecaprevir/pibrentasvirglecaprevir/pibrentasvir will increase the level or effect of sulfasalazine by decreasing metabolism. Use Caution/Monitor. Glecaprevir/pibrentasvir may increase plasma concentration of BCRP substrates.glimepiridesulfasalazine increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.glipizidesulfasalazine increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.glyburidesulfasalazine increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.griseofulvingriseofulvin decreases levels of sulfasalazine by unknown mechanism. Use Caution/Monitor.heparinheparin and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.horse chestnut seedsulfasalazine and horse chestnut seed both increase anticoagulation. Use Caution/Monitor.hydralazinesulfasalazine decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.hydrochlorothiazidesulfasalazine increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocortisonesulfasalazine, hydrocortisone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.ibuprofenibuprofen and sulfasalazine both increase anticoagulation. Use Caution/Monitor.ibuprofen and sulfasalazine both increase serum potassium. Use Caution/Monitor.ibuprofen IVibuprofen IV will increase the level or effect of sulfasalazine by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.ibuprofen IV and sulfasalazine both increase anticoagulation. Use Caution/Monitor.ibuprofen IV and sulfasalazine both increase serum potassium. Use Caution/Monitor.indapamidesulfasalazine increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.indomethacinindomethacin and sulfasalazine both increase anticoagulation. Use Caution/Monitor.indomethacin and sulfasalazine both increase serum potassium. Use Caution/Monitor.irbesartanirbesartan and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of irbesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.irbesartan, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.isoproterenolsulfasalazine increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.ketoprofenketoprofen and sulfasalazine both increase anticoagulation. Use Caution/Monitor.ketoprofen and sulfasalazine both increase serum potassium. Use Caution/Monitor.ketorolacketorolac and sulfasalazine both increase anticoagulation. Use Caution/Monitor.ketorolac and sulfasalazine both increase serum potassium. Use Caution/Monitor.ketorolac intranasalketorolac intranasal and sulfasalazine both increase anticoagulation. Use Caution/Monitor.ketorolac intranasal and sulfasalazine both increase serum potassium. Use Caution/Monitor.L-methylfolatesulfasalazine decreases effects of L-methylfolate by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Signs of folate deficiency reported.labetalollabetalol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.levalbuterolsulfasalazine increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.levomilnacipranlevomilnacipran, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs.lisinoprilsulfasalazine decreases effects of lisinopril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.lisinopril, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.lithiumsulfasalazine increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.lornoxicamlornoxicam and sulfasalazine both increase anticoagulation. Use Caution/Monitor.lornoxicam and sulfasalazine both increase serum potassium. Use Caution/Monitor.losartanlosartan and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.losartan, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.meclofenamatemeclofenamate and sulfasalazine both increase anticoagulation. Use Caution/Monitor.meclofenamate and sulfasalazine both increase serum potassium. Use Caution/Monitor.mefenamic acidmefenamic acid and sulfasalazine both increase anticoagulation. Use Caution/Monitor.mefenamic acid and sulfasalazine both increase serum potassium. Use Caution/Monitor.meloxicammeloxicam and sulfasalazine both increase anticoagulation. Use Caution/Monitor.meloxicam and sulfasalazine both increase serum potassium. Use Caution/Monitor.mesalaminemesalamine, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity.metaproterenolsulfasalazine increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.methazolamidemethazolamide, sulfasalazine. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.methyclothiazidesulfasalazine increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .methylprednisolonesulfasalazine, methylprednisolone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.metolazonesulfasalazine increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.metoprololmetoprolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of metoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.milnacipranmilnacipran, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.mistletoesulfasalazine increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.moexiprilsulfasalazine decreases effects of moexipril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.moexipril, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.moxisylytesulfasalazine decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mycophenolatesulfasalazine will increase the level or effect of mycophenolate by acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.nabumetonenabumetone and sulfasalazine both increase anticoagulation. Use Caution/Monitor.nabumetone and sulfasalazine both increase serum potassium. Use Caution/Monitor.nadololnadolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.nafcillinsulfasalazine decreases effects of nafcillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.naproxennaproxen and sulfasalazine both increase anticoagulation. Use Caution/Monitor.naproxen and sulfasalazine both increase serum potassium. Use Caution/Monitor.nebivololnebivolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of nebivolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.nefazodonenefazodone, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.nettlesulfasalazine increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.norepinephrinesulfasalazine increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.olmesartanolmesartan and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may